Screener
Maze Therapeutics MAZE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Interest and other income, net | 4,239 | 2,795 | 7,450 | 5,410 |
| Interest expense | (931) | — | (1,797) | — |
| Total other income, net | 3,308 | 2,795 | 5,653 | 5,410 |
| Net loss | $(44,727) | $(33,679) | $(68,935) | $(66,465) |
| Net loss per share, basic and diluted: | $(0.76) | $(0.77) | $(1.22) | $(1.83) |
| Weighted-average shares of common stock outstanding used to compute net loss per share, basic and diluted: | 58,995,934 | 43,797,421 | 56,460,660 | 36,254,828 |
| Comprehensive loss: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's other income (expense)?
- Maze Therapeutics (MAZE) reported other income (expense) of $3.31M in Q2 2026.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Maze Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude